Trial Profile
An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Enitociclib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer; Vincerx Pharma
- 14 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2022 Results (n=17) of a pooled safety analysis from two clinical studies: NCT04978779 and NCT02635672 presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2022 According to a Vincerx Pharma media release, updated data from 20 patients, 16 NHL from VNC-152-101 (NCT02635672) and 4 CLL patients from VNC-152-102 (NCT04978779) were presented at the 64th American Society of Hematology (ASH) Annual Meeting 2022.